Health · 6 views
Residual Disease in Spondyloarthritis: What's Being Missed by DMARDs?
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 6 Community interest
Brief read Under 1 min brief 31 words
Summary
(MedPage Today) -- In spondyloarthritis (SpA), the wealth of biologic and disease-modifying anti-rheumatic drug (DMARD) options still leaves some patients unsatisfied with their treatment outcomes, most likely due to residual disease.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
Part of Dmards coverage 4 tracked stories
More from Health
Continue reading recent Health coverage
- Study shows AI may improve patient discharge summariesContinue reading
- Postop morbidity lower with laparoscopic versus open resection of colorectal liver metastasesContinue reading
- First Guidelines for Cancer Caregivers Address Key Information Void in CareContinue reading
- Ensuring health equity with the use of AIContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow